Crohn’s Disease Diagnostics and Therapeutics Market (2020 - 2025)

The Crohn’s Disease Diagnostics and Therapeutics Market is Segmented by Diagnostics (Blood Test, Fecal Test, Colonoscopy, Flexible Sigmoidoscopy, Computerized Tomography, Magnetic Resonance Imaging, Capsule Endoscopy, and Other Diagnostic Tests), Therapeutics, and Geography.

Market Snapshot

Study Period:

2016-2024

Base Year:

2019

Fastest Growing Market:

Asia Pacific

Largest Market:

North America

Major Players:

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Market Overview

The Crohn's disease diagnostics and therapeutics market is estimated to register a CAGR  of 3.1% during the forecast period. Crohn’s disease (CD) is an inflammatory bowel disease (IBD) that can affect any part of the gastrointestinal tract, from mouth to the anus. It is caused by a combination of environmental, immune, and bacterial factors, in genetically predisposed individuals.

Increasing awareness of Crohn's disease, coupled with rising initiatives by regulatory bodies for the development of novel treatment options, is expected to provide the market with high growth potential.

Scope of the Report

Crohn’s disease (CD) is an inflammatory bowel disease (IBD) that can affect any part of the gastrointestinal tract from mouth to the anus. It is caused by a combination of environmental, immune, and bacterial factors, in genetically predisposed individuals.

Diagnostics
Blood Test
Fecal Test
Colonoscopy
Flexible Sigmoidoscopy
Computerised Tomography
Magnetic Resonance Imaging
Other Diagnostic Tests (Capsule Endoscopy etc)
Treatment
Medication
Anti-inflammatory Agents
Immunosuppressants
Analgesics and Antipyretics
Surgery
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Anti-inflammatory Agents Led the Market in 2018

Anti-inflammatory agents continued to lead as the largest sub-segment under the therapeutics segment of the market, in 2018, due to their higher efficacy, compared to immunosuppressant and analgesic. Immune system suppressors are expected to be the fastest-growing segment owing to the reduction in surgeries and hospitalization rates.

A specific category of anti-inflammatory agents includes non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs are among the most commonly used medication for the treatment of Crohn's disease.

To understand key trends, Download Sample Report

North America Holds the Largest Market Share

North America holds the largest market share in the Crohn's disease diagnostics and therapeutics market, due to the increasing prevalence of Crohn's disease in the region. Additionally, the Asia-Pacific region is expected to register high growth during the forecast period.

According to the Center for Disease Control and Prevention (CDC), it is currently estimated that about 1.3 million people suffer from inflammatory bowel disorder (IBD), in the United States. IBD prevalence includes the incidence of ulcerative colitis (UC) and Crohn's disease. In this region, urbanization is a potential contributing factor to the increasing prevalence of Crohn's disease. The incidence of CD is attributed to the result of the “westernization” of lifestyles, such as changes in diet, smoking, differences in exposure to sunlight, pollution, and industrial chemicals.

Overall, Crohn’s disease affects North American and Western European countries more heavily than others, with more than 750,000 people living with Crohn's disease in the United States alone.

To understand geography trends, Download Sample Report.

Competitive Landscape

The Crohn's disease diagnostics and therapeutics market has growth opportunities both in the developing and developed nations of the world. However, the US region controls a majority of the market share, which can be attributed to the higher prices of pharmaceuticals and greater prevalence of diagnosed cases of Crohn’s disease in the region. The higher share of the US market can also be attributed to the high annual cost of therapy (ACOT) of  Stelara (Johnson & Johnson) and the ACOT of Risankizumab (AbbVie) in the US market.

Table Of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Multiple Symptoms Associated with the Disease Requiring Individual Therapeutic Attention

      2. 4.2.2 Demand for Prompt Diagnosis

      3. 4.2.3 Affected Population Increasing with Time

    3. 4.3 Market Restraints

      1. 4.3.1 No Specific Treatment or Drug Available in the Market

      2. 4.3.2 Lack of Awareness among the People and Symptom Similarity with Other Gastrointestinal Diseases

      3. 4.3.3 Lack of Cost-effective Treatment

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 Diagnostics

      1. 5.1.1 Blood Test

      2. 5.1.2 Fecal Test

      3. 5.1.3 Colonoscopy

      4. 5.1.4 Flexible Sigmoidoscopy

      5. 5.1.5 Computerised Tomography

      6. 5.1.6 Magnetic Resonance Imaging

      7. 5.1.7 Other Diagnostic Tests (Capsule Endoscopy etc)

    2. 5.2 Treatment

      1. 5.2.1 Medication

        1. 5.2.1.1 Anti-inflammatory Agents

        2. 5.2.1.2 Immunosuppressants

        3. 5.2.1.3 Analgesics and Antipyretics

      2. 5.2.2 Surgery

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East & Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East & Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Abbvie Inc.

      2. 6.1.2 Celgene Corporation

      3. 6.1.3 Genetech

      4. 6.1.4 Janssen Biotech Inc.

      5. 6.1.5 Johnson & Johnson

      6. 6.1.6 Pfizer Inc.

      7. 6.1.7 Prometheus Laboratories Inc. (Nestle)

      8. 6.1.8 Salix Pharmaceuticals Inc. (Valeant Pharmaceuticals)

      9. 6.1.9 Takeda's Pharmaceutical Ltd

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

Related Reports